What is Traws Pharma, Inc. (TRAW) stock price today?

Traws Pharma, Inc. (TRAW) is currently trading at $0.45, down 7.31% today.

What is TRAW P/E ratio?

Traws Pharma, Inc.'s P/E ratio is -0.96. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is TRAW return on equity (ROE)?

Traws Pharma, Inc.'s return on equity (ROE) is 353.43%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Traws Pharma, Inc.'s market cap?

Traws Pharma, Inc. has a market capitalization of $6.78M.

NASDAQ · Biotechnology

Traws Pharma, Inc. (TRAW) Stock

$0.45 -7.31% NASDAQ: TRAW Healthcare

Valuation

Metric	Value
Price	$0.45
Market Cap	$6.78M
P/E Ratio	-0.96
P/B Ratio	-0.96
P/S Ratio	2.43
EPS (TTM)	$0.82
52-Week High	$3.27
52-Week Low	$0.43
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	353.43%
ROA	-128.70%
ROCE	283.33%
Gross Margin	-600.00%
Operating Margin	-600.00%
Net Margin	300.00%
Debt/Equity	0.00
Current Ratio	0.73

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$3.0M
Operating Profit	$-16.0M	$-20.0M	$-20.0M	$-49.0M	$-18.0M
Net Profit	$-16.0M	$-19.0M	$-19.0M	$-55.0M	$9.0M
EPS	$-24.01	$-22.68	$-22.57	$-35.21	$0.82
Op Margin	-7299.1%	-8684.5%	-8981.4%	-21835.4%	-640.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$55.0M	$39.0M	$23.0M	$25.0M	$11.0M
Total Liabilities	$9.0M	$11.0M	$12.0M	$57.0M	$11.0M
Cash	$55.0M	$39.0M	$21.0M	$21.0M	$4.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program MT Newswires · Jun 22, 2026 Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program GlobeNewswire · Jun 22, 2026 SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls The Fly · Jun 18, 2026 Top Premarket Decliners MT Newswires · Jun 15, 2026 Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell MT Newswires · Jun 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-19.0M	$-16.0M	$-18.0M	$-30.0M	$-18.0M
Investing Cash Flow	$0	$0	$0	$-4.0M	$-5.0M
Financing Cash Flow	$1.0M	$0	$0	$0	$-2.0M
Net Cash Flow	$36.0M	$-16.0M	$-18.0M	$1.0M	$-18.0M
Free Cash Flow	$-19.0M	$-16.0M	$-18.0M	$-30.0M	$-21.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-0.29
FCF Yield	-73.13%
Quick Ratio	0.43
Interest Coverage	0.00
Return 1Y	-55.78%
Return 3Y	-97.64%
Return 5Y	-99.49%

Ownership

Insiders Held5.38%

Institutions Held43.92%

Institutions Float Held46.42%

Institutional Holder	Shares	Report Date
Adage Capital Partners GP L.L.C.	730,000	2026-03-31
Ikarian Capital, LLC	678,142	2026-03-31
Orbimed Advisors LLC.	605,531	2026-03-31
Squadron Capital Management LLC	511,714	2026-03-31
Dauntless Investment Group, LLC	416,998	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BOLTBolt Biotherapeutics, Inc.	$4.25	+16.44%	-0.22	$8.17M	0.00%
BRTXBioRestorative Therapies, Inc.	$1.91	+1.06%	-0.10	$2.64M	0.00%
CINGCingulate Inc.	$4.89	+0.20%	-0.95	$65.86M	0.00%
COCPCocrystal Pharma, Inc.	$1.07	+0.00%	-1.49	$14.75M	0.00%
DWTXDogwood Therapeutics, Inc.	$1.43	+1.42%	-0.18	$48.09M	0.00%

About Traws Pharma, Inc.

Traws Pharma, Inc. is led by CEO Iain D. Dukes, employs 6 people, headquartered in US, publicly traded since 2013.

Traws Pharma, Inc. (TRAW) stock trades at $0.45 with a market capitalization of $6.78M. The stock is valued at a price-to-earnings (P/E) ratio of -0.96, price-to-book of -0.96, price-to-sales of 2.43. Over the past 52 weeks the stock has ranged between $0.43 and $3.27, and currently trades 86.2% below its 52-week high.

On profitability, Traws Pharma, Inc. generates a return on equity (ROE) of 353.43% — well above the market average, a sign of a high-quality business, return on capital employed of 283.33%, an operating margin of -600.00%, a net profit margin of 300.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides